Centre allows Bharat Biotech to begin commercial exports of Covaxin

Bharat Biotech made 55 million doses of Covaxin in October, and aims to make 80 million doses in December.

Sohini Das Mumbai
Bharat Biotech, Covaxin

Photo: Shutterstock

Paving the way for commercial exports of Covid-19 vaccines to start from India, the Centre allowed Hyderabad-based vaccine maker Bharat Biotech to start commercial exports of Covaxin on Tuesday, according to sources in the know. 
A few days back, its peer Pune’s Serum Institute of India (SII), was allowed to export to the WHO-led vaccine initiative COVAX.
Bharat Biotech did not wish to comment on the matter. SII, too, did not confirm if it got a nod to start commercial bilateral exports from the Indian government.

Also Read

Booster dose: Bharat Biotech's nasal vaccine may be used with Covaxin

WHO grants much-awaited emergency use listing to Bharat Biotech's Covaxin

Covaxin 77.8% effective against symptomatic Covid-19: Bharat Biotech

Bharat Biotech says higher pricing of Covaxin required in private markets

Bharat Biotech's Covaxin effective against Delta plus variant, says study

Central Vista: 6 firms submit technical bids to construct Executive Enclave

Blade India to induct five new H125 helicopters, ties up with Airbus

Coal India aims at Rs 40,000-50,000 cr capex in 4-5 years: Chairman

Acer India, Dixon Tech partner to manufacture 500,000 laptops annually

Panasonic India aims 10% growth, top-line of Rs 9,600 crore in FY22

First Published: Nov 25 2021 | 6:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to